Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia

Inclusion Criteria:

Key Inclusion Criteria

1. Prior participation in and the successful completion of the R727-CL-1003 study.

2. Patients must be on a stable daily statin regimen for at least 3 weeks before prior to
entry into the study

3. A negative urine pregnancy at the screening/baseline visit for women of childbearing
potential

Exclusion Criteria:

Key Exclusion Criteria

1. Reported a drug-related SAE or drug-related clinical or laboratory AE in the
R727-CL-1003 study that resulted in early termination or withdrawal

2. Significant protocol deviation in R727-CL-1003, such as non-compliance by the
investigator or patient

3. LDL apheresis within 12 months before the screening/baseline visit